Skip to content

Study · Non-randomized trial · n = 64 · 2011

1 result

Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).

Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM

The Journal of clinical endocrinology and metabolism12 Oct 2011Cited by 81 (Europe PMC)

PMID21994958 (opens in a new tab)PMCIDPMC3232610 (opens in a new tab)DOI10.1210/jc.2011-0587 (opens in a new tab)PepBankPUB-21994958
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, undercarboxylated osteocalcin increased with PTH(1-84) administration.

    In plain wordsIn women with osteoporosis, undercarboxylated osteocalcin increased during PTH treatment.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseUndercarboxylated osteocalcin
    Study

    n = 64

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ucOC levels increased with PTH(1-84) and decreased with alendronate administration (P ≤ 0.01 for both treatment groups).
    1 context sentence
    Summary · context
    We measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) or alendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.